199 related articles for article (PubMed ID: 19481800)
1. Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.
Breccia M; Palandri F; Iori AP; Colaci E; Latagliata R; Castagnetti F; Torelli GF; Usai S; Valle V; Martinelli G; Rosti G; Foà R; Baccarani M; Alimena G
Leuk Res; 2010 Feb; 34(2):143-7. PubMed ID: 19481800
[TBL] [Abstract][Full Text] [Related]
2. Superiority of allogeneic hematopoietic stem cell transplantation to nilotinib and dasatinib for adult patients with chronic myelogenous leukemia in the accelerated phase.
Xu L; Zhu H; Hu J; Wu D; Jiang H; Jiang Q; Huang X
Front Med; 2015 Sep; 9(3):304-11. PubMed ID: 26100855
[TBL] [Abstract][Full Text] [Related]
3. Second-generation tyrosine kinase inhibitors combined with stem cell transplantation in patients with imatinib-refractory chronic myeloid leukemia.
Zhao Y; Luo Y; Shi J; Cai Z; Huang H
Am J Med Sci; 2014 Jun; 347(6):439-45. PubMed ID: 24553398
[TBL] [Abstract][Full Text] [Related]
4. [Sustained remission with allogeneic peripheral blood stem cell transplantation and subsequent maintenance therapy with dasatinib in a patient with myeloblastic crisis of imatinib-resistant CML].
Narita T; Kayukawa S; Yoshida T; Kusumoto S; Kataoka T
Rinsho Ketsueki; 2013 Mar; 54(3):279-83. PubMed ID: 23676643
[TBL] [Abstract][Full Text] [Related]
5. Targeted chronic myeloid leukemia therapy: Seeking a cure.
Fausel C
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
[TBL] [Abstract][Full Text] [Related]
6. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F;
Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665
[TBL] [Abstract][Full Text] [Related]
7. A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia.
Francis S; Lucas C; Lane S; Wang L; Watmough S; Knight K; Bell J; Kaleel-Rahman M; Lee E; O'Brien D; Butt NM; Sadik W; De Soysa L; Seale JR; Salim R; Clark RE
Leuk Res; 2013 Jul; 37(7):752-8. PubMed ID: 23618689
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome of hematopoietic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph + ALL): experience from a single institution.
Doki N; Ohashi K; Oshikawa G; Kobayashi T; Kakihana K; Sakamaki H
Pathol Oncol Res; 2014 Jan; 20(1):61-6. PubMed ID: 23821455
[TBL] [Abstract][Full Text] [Related]
9. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
Jabbour E; Cortes J; Kantarjian HM; Giralt S; Jones D; Jones R; Giles F; Andersson BS; Champlin R; de Lima M
Blood; 2006 Aug; 108(4):1421-3. PubMed ID: 16601247
[TBL] [Abstract][Full Text] [Related]
10. Imatinib combined with myeloablative allogeneic hematopoietic stem cell transplantation for advanced phases of chronic myeloid leukemia.
Luo Y; Zhao Y; Tan Y; Shi J; Han X; Zheng Y; Li L; He J; Xie W; Ye X; Cai Z; Lin M; Huang H
Leuk Res; 2011 Oct; 35(10):1307-11. PubMed ID: 21354617
[TBL] [Abstract][Full Text] [Related]
11. [Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
Cheng Z; Zhao L; Chen G; Wu D; Qiu H; Tang X; Fu C; Jin Z; Chen F; Xue S; Sun A
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):114-9. PubMed ID: 24606651
[TBL] [Abstract][Full Text] [Related]
12. Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity.
Jabbour E; Cortes J; Kantarjian H; Giralt S; Andersson BS; Giles F; Shpall E; Kebriaei P; Champlin R; de Lima M
Cancer; 2007 Jul; 110(2):340-4. PubMed ID: 17559140
[TBL] [Abstract][Full Text] [Related]
13. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Ottmann OG; Pfeifer H
Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
Cortes J; Kim DW; Raffoux E; Martinelli G; Ritchie E; Roy L; Coutre S; Corm S; Hamerschlak N; Tang JL; Hochhaus A; Khoury HJ; Brümmendorf TH; Michallet M; Rege-Cambrin G; Gambacorti-Passerini C; Radich JP; Ernst T; Zhu C; Van Tornout JM; Talpaz M
Leukemia; 2008 Dec; 22(12):2176-83. PubMed ID: 18754032
[TBL] [Abstract][Full Text] [Related]
15. [Efficacy of dasatinib in treatment of imatinib-resistant BCR/ABL positive leukemia].
Zhu Y; Pan LQ; Qian SX; Song P; Yu H; Zhang SJ; Ge Z; Hong M; Tian T; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Jun; 21(3):581-6. PubMed ID: 23815902
[TBL] [Abstract][Full Text] [Related]
16. Excellent therapeutic results achieved in chronic myeloid leukemia patients with front-line imatinib and early treatment modifications in suboptimal responders: a retrospective study on 91 unselected patients.
Cerrano M; Crisà E; Pregno P; Aguzzi C; Riccomagno P; Boccadoro M; Ferrero D
Am J Hematol; 2013 Oct; 88(10):838-42. PubMed ID: 23757199
[TBL] [Abstract][Full Text] [Related]
17. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in second chronic phase attained by imatinib after onset of blast crisis.
Wang Y; Wu D; Sun A; Jin Z; Qiu H; Miao M; Tang X; Fu Z
Int J Hematol; 2008 Mar; 87(2):167-171. PubMed ID: 18288566
[TBL] [Abstract][Full Text] [Related]
19. Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.
Saussele S; Lauseker M; Gratwohl A; Beelen DW; Bunjes D; Schwerdtfeger R; Kolb HJ; Ho AD; Falge C; Holler E; Schlimok G; Zander AR; Arnold R; Kanz L; Dengler R; Haferlach C; Schlegelberger B; Pfirrmann M; Müller MC; Schnittger S; Leitner A; Pletsch N; Hochhaus A; Hasford J; Hehlmann R;
Blood; 2010 Mar; 115(10):1880-5. PubMed ID: 19965667
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic phase.
Inokuchi K; Kumagai T; Matsuki E; Ohashi K; Shinagawa A; Hatta Y; Takeuchi J; Yoshida C; Wakita H; Kozai Y; Shirasugi Y; Fujisawa S; Iwase O; Yano S; Okamoto S; Oba K; Sakamoto J; Sakamaki H
J Clin Exp Hematop; 2014; 54(3):197-204. PubMed ID: 25501110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]